Tag: biotech

Radar Therapeutics
United States

Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular RNA Sensors

BERKELEY, Calif. – Radar Therapeutics, a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC and other investors. The financing will support advancement of Radar’s internal programs, team expansion and partnering. “Like … Continue reading Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular RNA Sensors

Impact Newswire
Scenic Biotech
Europe

Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets Scenic to receive an upfront payment and potential additional payments contingent on the achievement of research, development and commercial milestones AMSTERDAM – Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into … Continue reading Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Impact Newswire
Domain Therapeutics
Europe, Global

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

February 27, 2024 07:10 AM Eastern Standard Time STRASBOURG, France & MONTREAL & BOSTON–(BUSINESS WIRE)–Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO). Stephan will oversee the development of Domain’s proprietary … Continue reading Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Impact Newswire
Domain Therapeutics
Europe, Global

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

STRASBOURG, France & MONTREAL & BOSTON–(BUSINESS WIRE)–Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team. In his new position, Sean will lead corporate strategy and business development bringing broad and deep … Continue reading Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Impact Newswire